Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Bitcoin Trust (IBIT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

iShares Bitcoin TrustTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

iShares Bitcoin Trust vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Bitcoin Trust trades at $46.78 (market cap $68.92B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: iShares Bitcoin Trust and Regeneron Pharmaceuticals Inc are close in size by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares Bitcoin Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.

IBITREGN
Market Cap
$68.92B$76.40B
Volume
46,059,179626,381
Sector
Crypto-linkedHealth
52-Week High
$68.74$852.03
52-Week Low
$33.29$557.73
Typical Hold Time
40 Days107 Days
Enterprise Value
—$71.12B
Dividend Yield
—0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Bitcoin Trust

IBIT trades at $47.21, down 2.64% on the day, with technical indicators showing a bullish overall signal driven by moving averages. The stock faces immediate support at $46 and resistance at $48. Recent news highlights strong institutional interest with BlackRock's IBIT recording $196 million in daily inflows on October 1, 2026, signaling renewed investor confidence in Bitcoin-focused investment products.

The outlook remains cautiously optimistic given institutional inflows and technical strength, though the absence of traditional financial metrics like P/E and P/S limits fundamental analysis. Key risks include market volatility and regulatory uncertainty, while analyst sentiment appears mixed with technical indicators favoring bullish momentum near-term.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IBIT
52% Buy48% Sell
Avg holding period · 40 Days
REGN
98% Buy2% Sell
Avg holding period · 107 Days

Top news

Latest headlines on both assets

About iShares Bitcoin Trust

IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.

Read more on IBIT →

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN →